Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 232 Shares of Stock

Key Points

• Insider buying: Dr. Martens director Ije Nwokori purchased 232 shares at GBX 65 each, worth £150.80. This follows earlier purchases, including 118,516 shares bought for approximately £85,332 in June.
• Stock performance: DOCS shares rose 3.5% to GBX 67.30, but remain below their 50-day moving average of GBX 76.82 and well below the one-year high of GBX 100.87.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus, with two Buy ratings and one Hold rating and an average price target of GBX 105.

Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori acquired 232 shares of the company's stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average price of GBX 65 per share, with a total value of £150.80.

Ije Nwokori also recently made the following trade(s):

• On Tuesday, August 11th, Ije Nwokori acquired 179 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 84 per share, for a total transaction of £150.36.
• On Thursday, June 25th, Ije Nwokori bought 118,516 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 72 per share, with a total value of £85,331.52.

Dr. Martens Trading Up 3.5%

Shares of DOCS stock traded up GBX 2.30 on Wednesday, reaching GBX 67.30. 340,241 shares of the stock were exchanged, compared to its average volume of 6,982,917. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. Dr. Martens plc has a one year low of GBX 59.15 and a one year high of GBX 100.87. The stock has a market cap of £644.16 million, a PE ratio of 28.04, a P/E/G ratio of 6.40 and a beta of 0.26. The stock has a 50 day moving average price of GBX 76.82 and a 200 day moving average price of GBX 70.51.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on DOCS shares. Royal Bank Of Canada restated a "sector perform" rating and set a GBX 100 target price on shares of Dr. Martens in a research report on Tuesday, June 2nd. Berenberg Bank dropped their price target on shares of Dr. Martens from GBX 114 to GBX 110 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Dr. Martens has an average rating of "Moderate Buy" and an average target price of GBX 105.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot - named after the date it was produced - rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, "Docs" or "DM's" were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.